첫 번째 재발에서 Epcoritamab에 대한 반응 적응 : 재발/내화성 큰 B 세포 림프종 환자에서 Eptoritamab의 효능을 평가하는 연구. (REPIFIR)
첫 번째 재발에서 Epcoritamab에 대한 반응 적응 : 재발/내화성 큰 B 세포 림프종 환자에서 eptoritamab의 효능을 평가하기위한 II 상, 반응 적응, 오픈 라벨, 다기관 연구
phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.
연구 개요
상세 설명
Epcoritamab is a full-length bispecific IgG1 antibody directed against two proteins, CD3 on the T lymphocyte and CD20 on the lymphoma cell. This antibody redirects and activates T cells, generating an immune synapse that eventually eliminates malignant cells expressing CD20.
Previous studies have demonstrated that Epcoritamab has potent antitumor activity as a monotherapy agent, with a favorable and manageable safety profile.
Since its efficacy is so favorable it is reasonable to think that it could be an excellent option for first-relapse patients. However, to date, there is no data on this therapy's usefulness as second-line treatment. Therefore we intend to evaluate the efficacy of Epcoritamab as a treatment option for patients with first-relapse LBCL.
The purpose of this study is to determine the efficacy of Epcoritamab as second line treatment for LBCL patients. On the basis of the clinical experience, it is hypothesized that Epcoritamab would provide a better complete response rate (CRR) in comparison to Platinum-based immunochemotherapy (CRR=25%), Polatuzumab-Bendamustin Rituximab (CRR=40%) and Tafasitamab-Lenalidomide (CRR=43%).
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Auxi Moreno
- 전화번호: +34 683 636 850
- 이메일: amoreno@geltamo.com
연구 연락처 백업
- 이름: Ana María Méndez
- 전화번호: +34 942 203 450
- 이메일: administracion@geltamo.com
연구 장소
-
-
Andalusia
-
Seville, Andalusia, 스페인, 41013
- 모병
- Hospital Universitario Virgen del Rocío
-
연락하다:
- Fátima de la Cruz Vicente, MD
- 전화번호: +34 955 0132 61
- 이메일: fatimadelacruzv@gmail.com
-
-
Aragon
-
Zaragoza, Aragon, 스페인, 50009
- 모병
- Hospital Universitario Miguel Servet
-
연락하다:
- Araceli Rubio
- 전화번호: +34 976 765 690
- 이메일: arubiom@salud.aragon.es
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, 스페인, 07120
- 모병
- Hospital Universitario Son Espases
-
연락하다:
- Antonio Gutiérrez, MD
- 전화번호: 65115 +34 871 205 000
- 이메일: antoniom.gutierrez@ssib.es
-
-
Castille and León
-
Burgos, Castille and León, 스페인, 09006
- 모병
- Hospital Universitario de Burgos
-
연락하다:
- Francisco Javier Díaz
- 전화번호: 36071 +34 947 281 800
- 이메일: fcdiaz@saludcastillayleon.es
-
Salamanca, Castille and León, 스페인, 37007
- 모병
- Hospital Universitario de Salamanca
-
연락하다:
- Alejandro Martín García-Sancho, MD
- 전화번호: +34 923 291 100
- 이메일: amartingar@usal.es
-
-
Catalonia
-
Badalona, Catalonia, 스페인, 08916
- 모병
- ICO Badalona
-
연락하다:
- Juan Manuel Sancho
- 전화번호: +34 934 651 200
- 이메일: jsancho@iconcologia.net
-
Barcelona, Catalonia, 스페인, 08035
- 모병
- Hospital Universitari Vall d'Hebrón
-
연락하다:
- Pau Abrisqueta
- 전화번호: 4976 or 2697 +34 932 746 100
- 이메일: pau.abrisqueta9@gmail.com
-
-
Extremadura
-
Cáceres, Extremadura, 스페인, 10003
- 모병
- Hospital San Pedro de Alcántara
-
연락하다:
- Juan Miguel Bergua
- 전화번호: +34 927 621 540
- 이메일: jmberguaburg@gmail.com
-
-
Madrid
-
Madrid, Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre
-
연락하다:
- Ana Jiménez Ubieto, MD
- 전화번호: +34 917 792 809
- 이메일: anitiju@hotmail.com
-
Madrid, Madrid, 스페인, 28007
- 모병
- Hospital General Universitario Gregorio Marañón
-
연락하다:
- Mariana Bastos-Oreiro
- 전화번호: +34 914 269 826
- 이메일: bastosmariana@yahoo.com
-
Madrid, Madrid, 스페인, 28031
- 모병
- Hospital Universitario Infanta Leonor
-
연락하다:
- María Stefania Infante
- 전화번호: +34 911 919 114
- 이메일: mariastefania.infante@salud.madrid.org
-
Madrid, Madrid, 스페인, 28040
- 모병
- Hospital Universitario Fundación Jiménez Díaz
-
연락하다:
- Raúl Córdoba
- 전화번호: +34 915 504 880
- 이메일: raul.cordoba@fjd.es
-
-
Murcia
-
El Palmar, Murcia, 스페인, 30120
- 모병
- Hospital Virgen de la Arrixaca
-
연락하다:
- Almudena Cascales
- 전화번호: +34 968 369 532
- 이메일: almudena.cascales@gmail.com
-
-
Málaga
-
Marbella, Málaga, 스페인, 29603
- 모병
- Hospital Universitario Costa del Sol
-
연락하다:
- María Casanova
- 전화번호: +34 951 976 542
- 이메일: mariacasanova@yahoo.com
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, 스페인, 33011
- 모병
- Hospital Universitario Central de Asturias
-
연락하다:
- Angel Ramírez
- 전화번호: +34 985 652 489
- 이메일: apayer.angel@gmail.com
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, 스페인, 38320
- 모병
- Hospital Universitario de Canarias
-
연락하다:
- María José Rodríguez
- 전화번호: +34 922 678 000
- 이메일: rodriguezsalazarmariajose@gmail.com
-
-
Valencia
-
Valencia, Valencia, 스페인, 46017
- 모병
- Hospital Universitario Dr. Peset
-
연락하다:
- Eva María Donato
- 전화번호: +34 963 189 168
- 이메일: donato_eva@gva.es
-
Valencia, Valencia, 스페인, 46024
- 모병
- Hospital Universitario y Politécnico La Fe
-
연락하다:
- Rafael Andreu
- 전화번호: +34 961 244 868
- 이메일: andreu_raflap@gva.es
-
-
Vizcaya
-
Bilbao, Vizcaya, 스페인, 48013
- 모병
- Hospital Universitario de Basurto
-
연락하다:
- Cristina Barrenetxea
- 전화번호: +34 944 006 000
- 이메일: cristina.barrene@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Written informed consent must be obtained before any study-specific assessment is performed.
-
Age >18 years
-
Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell Lymphoma (PMBCL), High-grade B-cell lymphoma (HGBCL); and grade 3B Follicular Lymphoma.
Relapsed disease is defined as complete remission to first line therapy followed by a recurrence of the disease after a minimum of 6 months of completion of first-line therapy. A biopsy at the time of relapse is recommended but not mandatory.
Refractory disease is defined as no objective response to first line therapy (biopsy not mandatory if diagnostic sample available). Four groups of patients are eligible:
- PD as best response to first line therapy.
- SD as best response after at least 4 cycles of first line therapy.
- PR as best response after at least 6 cycles of first line therapy.
- CR and disease recurrence within < 6 months from the completion of first-line therapy.
-
Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.
-
At the investigator's discretion, the patient should not be a candidate for 1st relapse CAR-T therapy or unwilling to receive CAR-T therapy.
-
Patients must be autologous stem cell transplantation (ASCT)-ineligible: Age ≥65 and/or HTC-CI ≥3 or or unwilling to receive transplant.
-
PET positive disease.
-
Performance status according to Eastern Cooperative Oncology Group (ECOG) 0 to 2.
-
Patients meeting with the following hematology values:
- Hemoglobin ≥8 g/dl (transfusion support permitted but not within 7 days of screening lab collection)
- Absolute neutrophil count (ANC) ≥ 1/109/L (growth factor support allowed in case of bone marrow involvement).
- Absolute lymphocyte count ≥ 0.1/109/L,
- Platelet count ≥ 70/109/L (unless secondary to bone marrow involvement, OR ≥50x/109/L if documented bone marrow involvement). Platelet transfusions permitted but not within 7 days of screening lab collection.
-
Female patients of child-bearing potential must have a negative urine or serum pregnancy test at screening and agree to use highly effective methods of contraception (e.g., established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) upon enrollment according to the recommendations provided by Clinical Trial Facilitation Group (CTFG), during the treatment period and for 4 months after the last dose of study medication. Moreover, the patient must agree to ongoing pregnancy testing during the course of the study, and after study therapy has ended. This applies even if the patient practices complete and continued sexual abstinence.
Women not of childbearing potential are defined as: premenarchal; postmenopausal (greater than 50 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level greater than 40 IU per L or milli-International unit (mIU) per mL); permanently sterilized (e.g., bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy.
-
Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrollment according to the recommendations provided by CTFG, during the treatment period, and for 4 months following the last dose of investigational drug or agreement to remain abstinent. Agreement to refrain from donating blood or sperm during the study participation and for 4 months after the last dose of study medication.
-
Women must agree not to donate blood or oocytes during the course of the study and for 4 months after the last dose of study medication. Restrictions concerning blood donation apply as well to females who are not of childbearing potential. Men must also not donate sperm during the trial and for 4 months after receiving the last dose of study drug.
-
Females of childbearing potential must refrain from breastfeeding during the course of the study and for 4 months after the last dose of study medication.
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
-
Not included in other clinical trial or treated with an experimental drug.
Exclusion Criteria:
-
Patients who received more than one prior line of systemic therapy
-
Patients with detectable Central Nervous System (CNS) lymphoma
-
Significant organ function impairment:
- creatinine clearance calculated by Cockcroft-Gault ≤ 45 ml/min
- direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome),
- alanine transaminase (ALT) and aspartate aminotransferase (AST) >3 × ULN or >5 × ULN in cases of documented liver involvement.
- clinically relevant pleural effusion,
- left ventricular ejection fraction (LVEF) ≤ 45%
-
Serious accompanying disorder leading to impaired organ function causing significant clinical problems and reduced life expectancy of less than 3 months.
-
Have a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
-
Known clinically significant cardiac disease, including:
- Onset of unstable angina pectoris within 6 months of signing the patient informed consent form.
- Acute myocardial infarction within 6 months of signing the patient informed consent form.
- Congestive heart failure (grade III or IV as classified by the New York Heart Association.
- Left ventricular ejection fraction ≤45%.
-
Known past or current malignancy other than inclusion diagnosis, except for: Cervical carcinoma of Stage 1B or less; Non-invasive basal cell or squamous cell skin carcinoma; Non-invasive, superficial bladder cancer; Localized low grade prostate cancer (up to Gleason score 6); DCIS of the breast; Other malignancy that has been treated with curative intent and has remained in remission for 3 years.
-
Previous ASCT.
-
Prior anti-CD3 and CD20 bispecific antibodies therapy or prior treatment with tafasitamab.
-
Presence of severe infection that is uncontrolled or requiring IV antimicrobials for management.
-
History of HIV infection or acute or chronic active hepatitis B or C infection.
- Individuals with positive HIV serology may be included if negative viral load and CD4 >200/mm3. For being included, patients should have controlled disease and been on treatment for at least 1 year
- Individuals with history of hepatitis infection with positive antibodies (anti-HB and anti-HV) might be included if negative viral load (negative hepatitis B PCR). Patients who are HBcAb positive must receive HBV prophylaxis while on treatment. Patients with positive HbsAg are excluded. Patients who are hepatitis B PCR positive will be excluded. Patients who are hepatitis C RNA positive will be excluded.
-
Females who are pregnant or breastfeeding.
-
Richter's transformation or prior chronic lymphocytic leukemia (CLL).
-
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 4 weeks prior to Cycle 1 Day 1.
-
Recent major surgery (within 4 weeks before the start of Cycle 1 Day 1) other than for diagnosis.
-
Vaccination with a live vaccine or COVID-19 vaccination within 4 weeks prior to treatment.
-
History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure. History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies.
-
Close affiliation with the investigator (e.g. a close relative) or persons working at the study site.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: EPCO monotherapy
Epcoritamab in monotherapy will be administred until cycle 12. |
Patients will receive 12 cycles of Epcoritamab monotherapy. |
|
실험적: Combination therapy
3 cycles of Epcoritamab in monotherapy will be administred and then Epcoritamab will be administred with Tafasitamab and Lenalidomide from cycle 4 until cycle 15. |
Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy of Epcoritamab monotherapy
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR at any moment since initiation. The CRR will be assessed by PET-CT according to Lugano Classification and is defined as the proportion of patients who achieve a best response of complete response (CR) at any moment since initiation of Epcoritamab first administration. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy of Epcoritamab monotherapy after 3 cycles
기간: At the end of cycle 3 (each cycle is 28 days)
|
The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR, defined as the proportion of patients who achieve a best response of CR after 3 cycles of Epcoritamab administration. |
At the end of cycle 3 (each cycle is 28 days)
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by CRR
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per CRR (locally evaluated for Epcoritamab monotherapy; local and central evaluation for combination therapy). |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
|
Evaluation of MRD
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
The efficacy of Epcoritamab monotherapy and combination therapy will be evaluated by MRD (positive or negative) from ctDNA samples immediately before initiation of C3, C4, C7, C10, C12, C13, C15, End of Treatment (EoT) and cycles 18/24 (epcoritamab monotherapy) or cycles 21/27 (combination therapy). |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Evaluation of patients with negative MRD by PFS
기간: At cycle 3 visit (each cycle is 28 days).
|
The PFS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
|
Safety and tolerability
기간: Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
|
The safety and tolerability of Epcoritamab monotherapy and combination therapy are evaluated as follows:
|
Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
|
|
Efficacy of Epcoritamab Monotherapy and Combination therapy by ORR
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per ORR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab Monotherapy and combination therapy by DoR
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by DoCR
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoCR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by EFS
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per Event-free survival (EFS) at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by PFS
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per PFS at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab montherapy and combination therapy by OS
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per OS at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Evaluation of patients with negative MRD by OS
기간: At cycle 3 visit (each cycle is 28 days).
|
The OS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
|
Evaluation of patients with negative MRD by DoR
기간: At cycle 3 visit (each cycle is 28 days).
|
The DoR of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response of patients stopping treatment by PFS
기간: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
To compare the PFS of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination. |
At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment by ORR
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by ORR. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by DoR
기간: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by DoR in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
|
|
MRD negativity
기간: through study completion, an average of 5 years
|
Median duration of molecular response (MRD negativity). |
through study completion, an average of 5 years
|
|
Correlation between tumor volume and efficacy
기간: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
Correlation between Total Metabolic Tumor Volume (centrally evaluated) and study treatment efficacy determined by PFS and OS. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
|
ctDNA levels
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Descriptive analysis of dynamic changes in ctDNA levels |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between lymphocyte subsets and efficacy
기간: Through study completion, an average of 5 years.
|
Correlation between lymphocyte subsets and study treatment efficacy determined by ORR, CRR, DoR, PFS and OS and safety determined by type, frequency, and severity of adverse events. |
Through study completion, an average of 5 years.
|
|
Response of patients stopping treatment
기간: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
To compare the DoR of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination. |
At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by CRR
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by CRR. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy DoR
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by DoR, PFS and OS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by PFS
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by PFS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by OS
기간: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by OS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by PFS
기간: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by PFS in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by OS
기간: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by OS in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañon
- 수석 연구원: Pau Abrisqueta, Hospital Universitari Vall d'Hebrón
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- REPIFIR-AGR-GEL-23
- 2024-514440-86-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data obtained through this study may be provided to qualified researchers with academic interest in hematology diseases. All individual data collected during the trial will be available. Data shared will be coded, with no PHI included. Study protocol, statistical analysis plan, informed consent form and clinical study report will be also available. Information will be available beginning 6 months after final publication with no end date established. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 6 months after article publication. Access to trial IPD can be requested by qualified researchers and will be provided following review and approval of a research and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact to GELTAMO though the web page: https://www.geltamo.com/contacto
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .